Cargando…
Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
BACKGROUND: HPV is a major cancer-causing factor in both sexes in the cervix, vulva, vagina, anus, penis, oropharynx as well as the causal factor in other diseases such as genital warts and recurrent respiratory papillomatis. In the context of the arrival of a nonavalent HPV vaccine (6/11/16/18/31/3...
Autores principales: | Boiron, L., Joura, E., Largeron, N., Prager, B., Uhart, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833954/ https://www.ncbi.nlm.nih.gov/pubmed/27084683 http://dx.doi.org/10.1186/s12879-016-1483-5 |
Ejemplares similares
-
Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
por: Mennini, Francesco Saverio, et al.
Publicado: (2017) -
Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
por: Gee, Julianne, et al.
Publicado: (2016) -
Spotlight on the 9-valent HPV vaccine
por: Lopalco, Pier Luigi
Publicado: (2016) -
HPV prevalence in vulvar cancer in Austria
por: Pils, Sophie, et al.
Publicado: (2017) -
Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe
por: Uhart, Mathieu, et al.
Publicado: (2016)